Coronavirus Update: Pfizer-BioNTech vaccine’s efficacy fell to 84% over six months, US, Australia grapple with cases surge
|Despite the improving market sentiment, thanks to China’s conciliatory remarks and Fed’s reassurance, the latest coronavirus vaccines update and the relentless rise in the virus cases globally offer little reprieve to the markets.
According to data released on Wednesday, the effectiveness of the Pfizer-BioNTech COVID-19 vaccine fell from 96% to 84% over six months,
The preprint study showed that the efficacy “declined gradually” to 83.7% within six months, with an average decrease of about 6% every two months.
On the covid count front, Australia continues to battle the surge in infections, with Sydney reporting 239 new cases on Wednesday vs. 177 recorded a day ago.
Across the Pacific, rising cases have caused Twitter to shut down its offices in San Francisco and New York once again while Disney has reinstated mask mandate in its California and Florida parks.
Meanwhile, Germany reported 3,520 new cases of covid, with death toll rising by 10.
Related reads
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.